Format

Send to

Choose Destination
J Neuroimmunol. 2017 Dec 15;313:77-81. doi: 10.1016/j.jneuroim.2017.10.012. Epub 2017 Oct 21.

Amelioration of ongoing experimental autoimmune encephalomyelitis with fluoxetine.

Author information

1
Bellevue Neurology, Bellevue, WA 98004, United States.
2
Department of Pediatrics, University of Nebraska Medical Center, Omaha, NE 68198, United States. Electronic address: sidharth.mahapatra@unmc.edu.
3
Department of Arthritis and Clinical Immunology Research, Oklahoma Medical Research Foundation, Oklahoma City, OK 73104, United States.
4
Departments of Pediatrics and Neurology and Neurological Sciences, Stanford University School of Medicine, Palo Alto, CA 94305, United States.

Abstract

In patients with multiple sclerosis, the selective serotonin reuptake inhibitor, fluoxetine, resulted in less acute disease activity. We tested the immune modulating effects of fluoxetine in a mouse model of multiple sclerosis, i.e. experimental autoimmune encephalomyelitis (EAE). We show that fluoxetine delayed the onset of disease and reduced clinical paralysis in mice with established disease. Fluoxetine had abrogating effects on proliferation of immune cells and inflammatory cytokine production by both antigen-presenting cells and T cells. Specifically, in CD4 T cells, fluoxetine increased Fas-induced apoptosis. We conclude that fluoxetine possesses immune-modulating effects resulting in the amelioration of symptoms in EAE.

KEYWORDS:

EAE; Experimental autoimmune encephalomyelitis; Fluoxetine; Multiple sclerosis; Neuroinflammation; SSRI

PMID:
29153612
DOI:
10.1016/j.jneuroim.2017.10.012
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center